Published on December 2, 2013
According to Brand Equity report, Indian market is expected to grow at CAGR of 14-17% from 2012-2016. India always has had serious issues when faced with implementation of rules, Maharashtra FDA Commissioner Mahesh Zagade has been investing whether there is a pharmacist present in every chemist and where does India stand on preventing Adverse Drug Reaction (ADR). Industry is gaining investments from foreign companies to improve the technology and research standards. Advanced technology helps the Indian Pharma industry to come up with new medicines and making new variants of the product. According to recent report the growth of Indian Pharma sector has dropped to 9.8 % from 16.6 % compared to last year. Several issues hampering the Pharma sector are like delays in clinical trial approvals, issues over FDI policies, new pricing policy and uniform code for sales and licensing. MNC’s are the worst affected compared to domestic players. Government is planning for new measures on limiting the investments by foreign companies. The companies will be prohibited to gain 100 percent stake in the Indian companies and will get set of terms and conditions to follow in order to acquire Indian Pharma Company. The Pharma sector needs globalization for its overall win-win situation.
